Skip to main content
. 2013 May 8;71(3):379–404. doi: 10.1007/s00018-013-1343-z

Fig. 4.

Fig. 4

mH2A.2 loss correlates with melanoma malignancy. Immunostaining of mH2A.2 in benign nevi and metastatic melanoma specimens (representative samples shown at 20X magnification). mH2A.2 is visualized using DAB (brown) and nuclei by haematoxylin (blue). Note loss of staining in metastatic melanoma cells